ibrutinib

Broca®

in two doses of 140 and 420

It is available as an oral, coated tablet containing ibrutinib as the active ingredient, ibrutinib is an anticancer agent that acts as a potent irreversible tyrosine kinase inhibitor.

Packaging and pharmaceutical form:

30 coated tablets with patient information brochure.

Indications:

Lymphoma cancer (MCL)

Chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL)

Lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia: WM)

• Marginal zone lymphoma (MZL)

• Chronic graft-versus-host disease (cGVHD).

Amount and method of consumption:

The medicine should be taken according to the doctor's prescription.

Therapeutic effects and pharmacology:

Ibrutinib is a proton tyrosine kinase (BTK) inhibitor that helps shrink cancer cells.

This compound forms a covalent bond with the cysteine ​​residue in the active site of BTK (Cys481), leading to its inhibition. Inhibition of BTK is involved in B cell receptor signaling and therefore, the presence of ibrutinib prevents the phosphorylation of downstream substrates such as PLC-γ and is effective in reducing cancer cells.

side effects:

Among the most common side effects of ibrutinib:

Peripheral edema, increased blood pressure, fatigue, confusion, headache, anxiety, chills, skin rashes, skin infection, itching, increased serum urea level, decreased blood potassium, decreased serum albumin level, dehydration, diarrhea, nausea, inflammation of the oral mucosa, constipation , abdominal pain, nausea, vomiting, loss of appetite, indigestion, reflux, abdominal pain, urinary tract infection, thrombocytopenia, neutropenia, bruising, bleeding, hemoglobin decrease, dead blood, primary malignant neoplasm, infection, muscle pain, muscle spasm, pain joints, dry eye syndrome, increased tearing, blurred vision, decreased field of vision, upper respiratory tract infection, shortness of breath, cough, sinusitis, pneumonia, nosebleeds, pain in the pharynx and nose, bronchitis, fever

Common complications: atrial fibrillation, atrial fissure, ventricular tachycardia, intracranial hemorrhage, subdural hematoma, gastrointestinal bleeding, blood in the urine, non-melanoma skin cancer, anemia, bleeding after surgery, sepsis, increased creatinine

Drug interactions:

Because this product can interact with other medications, be sure to inform your doctor of the list of medications you are taking before starting to use it.

Avoid consuming grapefruit and its juice during the period of use because it may increase the level of ibrutinib in your body.

Precautions and warnings:

In case of bleeding, bruising and death, infection, blood toxicities such as neutropenia, thrombocytopenia, cardiac arrhythmia, increased blood pressure and tumor lysis syndrome, inform your doctor or pharmacist immediately.

Pregnancy and breastfeeding:

Administering ibrutinib during pregnancy can lead to fetal damage, that's why women of reproductive age are advised to use safe methods of contraception while taking this drug and for a period of one month after stopping the drug. Also, men using ibrutinib should not try to have children during the period of taking this drug until one month after stopping it.

There are no sufficient studies on the amount of ibrutinib in breast milk, depending on the doctor's opinion, a decision should be made about continuing breastfeeding or stopping it.

Maintenance:

Store at a temperature below 30 degrees Celsius, away from moisture and light and out of the reach of children.